Titrating slowly helps the gastrointestinal system adapt to the delayed gastric emptying and appetite suppression effects
GLP-1 is an endocrine hormone secreted by enteroendocrine L-cells located in the distal jejunum, ileum and colon that express the glucagon gene and produce proglucagon (Lee et al., 1990)
In the PIONEER 10 clinical trial, the outcomes of patients on varying doses of oral semaglutide versus dulaglutide were compared and included side effects
Patients should seek prompt medical guidance for severe or persistent vomiting, signs of dehydration, severe abdominal pain, fainting, symptoms of low blood sugar, inability to keep fluids down, worsening constipation with pain or bloating, or any symptom that feels unsafe
Dose schedule considerations by body weight The clinical trials used fixed doses (not weight-based dosing), which means a 200-pound person and a 300-pound person received the same milligram amount
For GLP-1 medications, insurers may require evidence that the patient has tried other treatments or that the medication is essential for managing weight loss in the presence of other conditions like type 2 diabetes, hypertension, or cardiovascular disease
